DVC Deutsche Venture Capital Achieves Further Successful Transactions And Exits Within Its Life Sciences Portfolio In The 1st Quarter 2005

Munich DVC Deutsche Venture Capital, one of Europe’s leading venture capital companies based in Munich, achieves further successful transactions and exits within its life sciences portfolio. In the 1st quarter of 2005, the mergers of G2M Cancer Drugs AG and TopoTarget A/S as well as of Igeneon AG and Aphton Corporation have successfully been accomplished; Ardana plc has successfully completed its IPO on the London Stock Exchange (LSE) on March 4th.

Back to news